Paul Tudor Jones Myovant Sciences Ltd. Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$24.03 - $27.02 $1.7 Million - $1.91 Million
70,746 New
70,746 $1.91 Million
Q1 2022

May 16, 2022
SELL
$11.38 - $16.4 $203,610 - $293,428
-17,892 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$14.31 - $23.87 $256,034 - $427,082
17,892 New
17,892 $279,000
Q1 2021

May 17, 2021
SELL
$20.46 - $25.18 $610,649 - $751,522
-29,846 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$13.8 - $27.62 $411,874 - $824,346
29,846 New
29,846 $824,000

Others Institutions Holding MYOV

# of Institutions
6
Shares Held
61.3K
Call Options Held
0
Put Options Held
0
View Full List

About Myovant Sciences Ltd.

MYOV Quotes by TradingView
  • Ticker MYOV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 96,802,800
  • Description
  • Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...
More about MYOV
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email